Reimbursement & HTA Strategy Roadmap
A client-specific, step-by-step roadmap defining HTA requirements, evidence needs, key risks, and country-specific reimbursement pathways for diagnostic technologies across European markets.
Aimed To
Biotech
Pharma
Diagnostics (IVD/CDx)
Market Access
Medical Affairs
HEOR
Regulatory
Strategy Teams
Challenge
Navigating HTA and reimbursement decisions across countries involves multiple pathways, timelines, and risk points, making it difficult to maintain a clear, coordinated strategy without a structured roadmap.
How It Works
- Define HTA and reimbursement objectives per market
- Map country-specific pathways, timelines, and decision points
- Align evidence requirements with HTA expectations
- Identify key risks and mitigation options
- Sequence actions into a clear, step-by-step roadmap
Why Buy
Provides a clear and actionable HTA and reimbursement plan, reducing uncertainty, anticipating risks, and enabling more confident decision-making across markets.
